title: Cost minimisation analysis of 12 or 24 weeks of peginterferon alfa-2b + ribavirin for hepatitis C virus.
abstract: BACKGROUND
  Pegylated interferon and ribavirin are at present the standard treatment for chronic hepatitis C virus (HCV) patients.
  
  
  OBJECTIVE
  The present economic evaluation compared 12 vs. 24 weeks of peginterferon alfa-2b + ribavirin treatments for HCV genotypes 2 or 3. Shortening the period of antiviral therapy is important in terms of adverse events and costs.
  
  
  METHODS
  Clinical evidence was based on the results of a multicentre, randomised controlled clinical trial (RCCT) conducted in Italy, which found that the shorter course of therapy was as effective as the 24-week course for patients with HCV genotypes 2 or 3 responding to treatment at 4 weeks. A cost minimisation analysis was performed. The analysis took the Italian National Health Service (INHS) point of view, thus only healthcare costs (drugs, medical consultations, diagnostic tests, hospital admissions) were considered. Healthcare activities were estimated by the RCCT principal investigators and were priced by applying the INHS tariffs and prices.
  
  
  RESULTS
  The total mean cost per patient was estimated at euro9,785 for the standard group and euro7,508 for the variable-duration group. Sensitivity analysis confirmed the robustness of the baseline results.
  
  
  CONCLUSIONS
  This study showed that the variable-duration regimen can be recommended as an efficient use of resources for patients from the INHS perspective.
authors.affiliation: CESAV, Centre for Health Economics, 'Mario Negri', Institute for Pharmacological Research, 24020, Ranica, (BG), Italy.
authors.forename: Paola
authors.initials: P
authors.lastname: De Compadri
authors.forename: Daniela
authors.initials: D
authors.lastname: Koleva
authors.forename: Alessandra
authors.initials: A
authors.lastname: Mangia
authors.forename: Nicola
authors.initials: N
authors.lastname: Motterlini Stat Sci
authors.forename: Livio
authors.initials: L
authors.lastname: Garattini
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D011092:Polyethylene Glycols; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D015203:Reproducibility of Results; D012254:Ribavirin / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b